Tag: cancer

VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (FSE: 7JO0) (the “Company” or “Rakovina”), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that its board of directors has approved the grant of an aggregate of 540,000 stock options (the “Options”) to certain consultants, employees, officers and directors of the Company pursuant to the Company’s Long Term Incentive Plan.

According to Towards FnB, the global fruit and vegetables market size is evaluated at USD 244 billion in 2025 and is forecasted to hit around USD 388.37 billion by 2034, growing at a CAGR of 5.3% during the forecast period from 2025 to 2034.

Innovative academic program contributes to a strong and sustainable talent pipeline for Canada’s national nuclear laboratories and Canadian nuclear sector

Un programme universitaire novateur contribue à un bassin de talents solide et durable pour les laboratoires nucléaires nationaux du Canada et le secteur nucléaire canadien

Allschwil, Switzerland, July 29, 2025

CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) received two different communications from the staff of the Nasdaq Listing Qualifications office of the Nasdaq Stock Market, LLC. The Company received the first notice from the Nasdaq Listings Qualifications office of the Nasdaq Stock Market LLC on July 23, 2025, informing the Company that as reflected in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC on July 21, 2025, the Company failed to comply with the $2.5 million stockholder’s equity required under Nasdaq Rule 5550(b)(1) (the “Equity Rule”) or any alternative standard under Nasdaq 5550(b).